Navigation Links
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Date:4/20/2012

operating expenses continue to exceed its net revenues, that CTI may not be able to further reduce its operating expenses, that CTI will continue to need to raise capital to fund its operating expenses and may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Media Contact:Dan Eramian
T: 206.272.4343
C: 206.854.1200
F: 206.272.4434
E: deramian@ctiseattle.com
www.celltherapeutics.com/media.htm

Investors Contact:Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.celltherapeutics.com/investors Cell Therapeutics, Inc.Condensed Consolidated Statements of Operations(In thousands, except for per share amounts)(unaudited)Three Months EndedMarch 31,20122011Operating expenses:Research and development$
8,170$
,494Selling, general and administrative9,9288,576  Total operating expenses18,09820,070Loss from operations(18,098)(20,070)Other income (expense):Investment and other income, net24063Interest expense(55)(389)Amortization of debt discount and issuance costs-(167)Foreign exchange gain384759Net loss before noncontrolling interest(17,529)(19,804)Noncontrolling interest8370Net loss attributable to CTI(17,446)(19,734)Dividends and deemed dividends on preferred stock-(31,283)Net loss attributable to CTI common shareholders$
(17,446)$
(51,017)Basic and diluted net loss per common share $
(0.09)$
(0.35)Shares used in calculation of basic
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Institute for Molecular Medicine Finland (FIMM), University of ... novel "man and machine" decision support system for ... described in PLOS One scientific journal ... computer vision algorithms similar to those used in ... the diagnostically most relevant areas. Tablet computers can ...
(Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... Could Drive Product Adoption in High-Growth Cell Therapy Market ... Dec. 16 BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), ... storage and cryopreservation media products for cells, tissues, and ... series of small animal safety studies at the Seattle-based ...
... Epeius Biotechnologies,Corporation, a leader in tumor-targeted gene ... for the platform targeting technologies and,molecular designs ... cancers and,metastatic lesions that have spread throughout ... and single-agent-efficacy, as well as,overall safety, Epeius ...
... SOUTH SAN FRANCISCO, Calif., Dec. 16 Anesiva,Inc. ... results showing that the Phase 3,trial evaluating Adlea(TM), ... efficacy endpoint of reducing post-surgical,pain versus placebo (p=0.03) ... surgery) at four to 48 hours after surgery. ...
Cached Biology Technology:BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 2BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 3BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 4Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4
(Date:8/22/2014)... . , Thanks ... in a way so as to align themselves symmetrically, ... University researchers are planning on looking into how PCFs ... being published today in the scientific journal Nature ... Everyone knows that at least from having boiled ...
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
(Date:8/22/2014)... 2015, American consumers will finally be able to purchase ... touted as zero-emissions vehicles, most of the cars will ... fuel that contributes to global warming. , Now scientists ... that uses an ordinary AAA battery to produce hydrogen ... current through two electrodes that split liquid water into ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3
... , Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a ... drug development services to industry, announced today that they ... an investigational medication for Type 2 Diabetes Mellitus.  The ... tolerability of multiple daily doses of the investigational medication ...
... chemical engineering researchers have created a new synthetic metabolic pathway ... percent increase in the production of biofuels. ... pathway known as glycolysis, a series of chemical reactions that ... precursors that cells need. Glycolysis converts four of the six ...
... has detected propylene, a chemical used to make food-storage ... moon Titan. This is the first definitive detection ... other than Earth. A small amount of propylene ... Infrared Spectrometer (CIRS). This instrument measures the infrared light, ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2NASA's Cassini spacecraft finds ingredient of household plastic in space 2
... The Fujifilm Life Science FLA-7000 excels at ... CBB-stained gel documentation. It features four easy-to-access ... and a filter for Imaging Plates) for ... a customizable choice of four kinds of ...
... has been optimized for the analysis of ... software to quickly and accurately locate and ... an ELISA plate or each section of ... been customized to incorporate standard ELISA analysis ...
For microscopy...
... General description: Humidity wells in the ... maintain chamber humidity and probe hydration around ... seal eliminates the risk of waterbath contamination. ... constant temperature waterbaths or hybridisation ovens. Linkage: ...
Biology Products: